A large genomic characterization study found specific somatic copy number alterations to have prognostic implications for metastasis, resistance, and novel therapeutic approaches in metastatic triple-negative breast cancer.
Accelerated partial breast irradiation (APBI) leads to the same rates of survival and toxicity as whole breast irradiation (WBI) while also producing significantly better cosmetic results, according to phase 3 trial results presented at European Society for Therapeutic Radiotherapy and Oncology (ESTRO) 35 (April 29-May 3, 2016; Turin, Italy).
Women younger than 45 years who opt for breast conserving therapy (BCT) over mastectomy may have a higher risk of developing a local recurrence over a 20-year period, according to research presented at European Society for Therapeutic Radiotherapy and Oncology (ESTRO) 35 (April 29-May 3, 2016; Turin, Italy).
Results from a clinical trial presented at the 2016 American Association for Cancer Research Annual Meeting (April 16-20; New Orleans, LA) identified two genetic biomarkers capable of predicting which patients with breast cancer would benefit from chemotherapy followed by tamoxifen.
A bone metastasis model has been created that simulates interactions between metastatic breast cancer cells and bone cells to determine effectiveness of different treatments, published in Nature Communications (published online April 21, 2017; doi:10.1038/ncomms15045).
Adding palbociclib to fulvestrant prolongs progression-free survival (PFS) compared with fulvestrant alone among pre- and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to research published in the Journal of Global Oncology (published online April 11, 2017; doi:10.1200/JGO.2016.008
Using body composition metrics to determine dosage of anthracyclines-taxane based chemotherapy for patients with breast cancer can reduce treatment-related toxicity, according to a study published in Clinical Cancer Research (published online January 31, 2017; doi:10.1158/1078-0432.CCR-16-2266).
Women with breast cancer are more likely to discontinue chemoprevention therapy if menopause-specific symptoms negatively impact their quality of life (QOL), according to a study published in the Journal of Clinical Oncology (February 2017;35:629-635).